Neuropathic Pain
Therapeutics Market: Introduction
According to the report, the
global neuropathic pain
therapeutics market was valued at US$ 5.8 Bn in 2019 and
is projected to expand at a CAGR of ~5% from 2020 to 2030.
Neuropathic pain can occur in different indications including diabetic
neuropathy, post-herpetic neuralgia, cancer-related pain, spinal cord injury,
and others. Drug classes used to treat neuropathic pain are anticonvulsants,
antidepressants, NSAIDs, opioids, steroids, and others. Moreover, rise in
prevalence of neuropathic pain and increase in geriatric population leading to
surge in cases of nerve pain among the population across the globe are boosting
the growth of the global market. North America dominated the global neuropathic
pain therapeutics market in 2019 and the trend is anticipated to continue
during the forecast period. Rise in adoption of neuropathic pain therapeutics
for treatment and increase in number of clinical trials for the development of
these products for different disorders fuel the growth of the market in the
region.
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=77666
Asia Pacific is expected to be a
highly lucrative market for neuropathic pain treatments during the forecast
period, owing to the increase in geriatric population, rise in awareness about
neuropathic conditions, and surge in focus of leading players toward targeting
developing countries such as India and China.
Rise in Geriatric
Population and Prevalence of Diabetic Neuropathy to Drive Market
Diabetes mellitus (DM) is a major
health problem globally. According to IDF 2019 data, global
prevalence of diabetes mellitus was 8.8% among adults, with the number expected
to rise to 10.4% by 2040. The prevalence of
peripheral neuropathy is estimated to be between 6% and 51% among
adults with diabetes depending on age, duration of diabetes, glucose control,
and type 1 or type 2 diabetes. An article published in the International
Journal of Endocrinology in 2019 stated that nearly 50% of
diabetics suffer from diabetic polyneuropathy. The increase in incidence of
neuropathic pain continues to encourage the use of pain management drugs,
thereby driving the global market.
The geriatric population is at a high
risk of neuropathic pain, as the incidence of several diseases that cause
neuropathic pain increases with age. Depending on their underlying health,
older adults with neuropathic pain could have to cope with multiple coexisting
diseases, polypharmacy, and impaired functional ability.
Request COVID Analysis on Neuropathic Pain Therapeutics Market –
https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=77666
An article published in NCBI in 2019 stated
that prevalence of chronic pain among the geriatric population is high
(estimated at 25% to 85%) and could adversely
affect their everyday functioning. According to population surveys in France,
Morocco, and the U.K. and a recent systematic review of epidemiological
studies, 6% to 10% prevalence of neuropathic pain was reported in these
countries. Hence, increase in geriatric population is expected to augment the
global neuropathic pain therapeutics market.
Anticonvulsants to
Dominate Market
In terms of drug class, the global
neuropathic pain therapeutics market has been divided into anticonvulsants,
antidepressants, NSAIDs, opioids, steroids, and others. The antidepressants
segment has been bifurcated into tricyclic antidepressants and serotonin-norepinephrine
reuptake inhibitors (SNRIs). The anticonvulsants segment dominated the global
neuropathic pain therapeutics market in 2019 and the trend is
likely to continue during the forecast period, owing to the increase in cases
of nerve pain and launch of new drugs. Lyrica is a major brand that dominates
the anticonvulsants market. Pfizer obtained market exclusivity for the drug in 2018.
Diabetic
Neuropathy to be Promising Segment
Based on indication, the global
neuropathic pain therapeutics market has been classified into diabetic
neuropathy, post-herpetic neuralgia, cancer-related pain, spinal cord injury,
and others. The diabetic neuropathy segment is expected to expand at the
highest CAGR during the forecast period. An article published in NCBI in 2019 indicated
that prevalence of neuropathic pain in the general population varies from as
little as 1% to as much as 7% to 8%. This
includes maximum incidence in diabetic patients (26%).
Oral to be
Preferred Route of Administration
Based on route of administration, the
global neuropathic pain therapeutics market has been segregated into oral,
topical, and others. The oral segment dominated the market in 2019.
Commonly used painkillers such as ibuprofen (NSAIDs) are not usually considered
effective in treating neuropathic pain. However, in some parts of the world,
these are commonly prescribed for neuropathic pain conditions. Surveys found
that between 18% and 47% of affected people reported using
NSAIDs specifically for neuropathic pain.
Request Customization on Neuropathic Pain Therapeutics Market Report –
https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=77666
Retail Pharmacies
to be Major Distribution Channel
In terms of distribution channel, the
global neuropathic pain therapeutics market has been categorized into retail
pharmacies, hospital pharmacies, and online pharmacies. The retail pharmacies
segment dominated the global neuropathic pain therapeutics market in terms of
revenue in 2019 and the trend is projected to continue during the forecast
period. Increase in the number of neuropathic pain drugs being dispensed
through retail pharmacies and rise in number of retail pharmacies in developing
countries make these pharmacies a major channel of distribution.
North America to
Dominate Global Market
The global neuropathic pain
therapeutics market has been segmented into five major regions: North America,
Europe, Asia Pacific, Latin America, and Middle East & Africa. North
America dominated the global market in 2019, followed by Europe.
North America accounted for a major share of the global neuropathic pain
therapeutics market in 2019, owing to the introduction of new
drugs and high prevalence of targeted diseases in developing countries such as
the U.S. The neuropathic pain therapeutics market in Asia Pacific is
anticipated to expand at a higher CAGR from 2020 to 2030. The
growth of the neuropathic pain therapeutics market in the region can be
attributed to rise in prevalence of disorders and increase in awareness about
the treatment in the region.
Buy Neuropathic Pain Therapeutics Market Report –
https://www.transparencymarketresearch.com/checkout.php?rep_id=77666<ype=S
Competition
Landscape
Pfizer, Novartis AG, and
GlaxoSmithKline are leading players in the global neuropathic pain therapeutics
market and hold majority market share. The global neuropathic pain therapeutics
market is fragmented in terms of number of players. Key players in the global
market include Pfizer, Novartis AG, AstraZeneca, GlaxoSmithKline, Eli
Lilly and Company, Mallinckrodt Pharmaceuticals, Johnson & Johnson, Abbott,
Endo Pharmaceuticals, Inc., Teva Pharmaceutical Industries Limited, and Merck
& Co., Inc. New product development through robust R&D
activities and mergers & acquisitions are the key strategies adopted by
these players to operate their business in the global neuropathic pain
therapeutics market.
Global Neuropathic
Pain Therapeutics Market: Segmentation
·
Neuropathic Pain Therapeutics Market, by Drug Class
o Anticonvulsants
o Antidepressants
§ Tricyclic
Antidepressants
§ Serotonin-norepinephrine
Reuptake Inhibitors (SNRIs)
o NSAIDs
o Opioids
o Steroids
o Others
·
Neuropathic Pain Therapeutics Market, by Indication
o Diabetic Neuropathy
o Post-herpetic
Neuralgia
o Cancer-related Pain
o Spinal Cord Injury
o Others
·
Neuropathic Pain Therapeutics Market, by Route of
Administration
o Oral
o Topical
o Others
·
Neuropathic Pain Therapeutics Market, by
Distribution Channel
o Retail Pharmacies
o Hospital Pharmacies
o Online Pharmacies
·
Neuropathic Pain Therapeutics Market, by Region
o North America
§ U.S.
§ Canada
o Europe
§ Germany
§ U.K.
§ France
§ Italy
§ Spain
§ Rest of Europe
o Asia Pacific
§ China
§ India
§ Japan
§ Australia & New
Zealand
§ Rest of Asia
Pacific
o Latin America
§ Brazil
§ Mexico
§ Rest of Latin
America
o Middle East &
Africa
§ GCC Countries
§ South Africa
§ Israel
§ Rest of Middle East
& Africa
About Us
Transparency Market Research is a
global market intelligence company, providing global business information
reports and services. Our exclusive blend of quantitative forecasting and
trends analysis provides forward-looking insight for thousands of decision
makers. Our experienced team of analysts, researchers, and consultants, uses
proprietary data sources and various tools and techniques to gather and analyze
information.
Our data repository is continuously
updated and revised by a team of research experts, so that it always reflects
the latest trends and information. With a broad research and analysis
capability, Transparency Market Research employs rigorous primary and secondary
research techniques in developing distinctive data sets and research material
for business reports.
Contact
Transparency Market Research,
90 State Street, Suite 700,
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com/
